what is known about trial:nct:NCT06599502

A Phase I/IIa Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD0022 as Monotherapy and in Combination With Anti-cancer Agents in Adult Participants With Tumours Harbouring a KRASG12D Mutation NCT06599502↗ Outcome: Stopped early

Computed from the knowledge API (getStudy); every record links to its source.